Biocorp: Novo Nordisk holds 97.8% of the capital
During the OPAS period, from September 7 to 27 inclusive, Novo Nordisk acquired 665,985 shares under the semi-centralized procedure and 343,223 shares through its designated buyer market member, at a unit price of 35 euros.
In all, the Danish pharmaceutical company holds 4,317,044 Biocorp shares, representing the same number of voting rights. The listing of Biocorp shares will remain suspended until the squeeze-out is implemented.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction